A world in which a simple blood draw will be sufficient for early cancer screening and liquid biopsy, enabling physicians to detect early cancers and to optimize patients’ treatment.
Caring about Human Health with Honesty – Adopting High Standard Solutions – Making a Difference Through Innovative Thinking – Teamwork – Partnership and Trust with Academy and Industry.
We provide accurate cancer screening and liquid biopsy from a routine blood draw, truly suitable for early cancer detection and for active patients’ management and monitoring.
We tackle innovative biological principles and evolving science and technologies to design and validate highly accurate diagnostic tests.
Our approach is based on the detection of fundamental drivers of cancer and cancer hallmarks shuttled by tumor exosomes as early sentinels of tumor occurrence.
Our tests are simple, reliable, and cost-effective. We offer scalable and user friendly test formats and provide them as open platform solutions.
Current investors are: Lonza, BioBalt Holding, BioFund, FinBiotech, and Black Swan Trade